The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CVKD | -36.76% | N/A | N/A | -86% |
| S&P | +13.22% | +85.17% | +13.11% | +72% |
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
No news articles found for Cadrenal Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 1.5% |
| Market Cap | $28.31M | 94.3% |
| Market Cap / Employee | $7.08M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$2.69M | -11.5% |
| EBITDA | -$2.73M | -11.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.86M | -11.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -328.18% | -219.4% |
| Return On Invested Capital | -38.96% | -52.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.36M | -7.2% |
| Operating Free Cash Flow | -$2.36M | -7.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.24 | 4.22 | 3.76 | 6.46 | 76.96% |
| Price to Tangible Book Value | 5.24 | 4.22 | 3.76 | 6.46 | 76.96% |
| Enterprise Value to EBITDA | -2.82 | -6.42 | -4.84 | -8.93 | 105.11% |
| Return on Equity | -140.8% | -208.6% | -340.3% | -468.0% | 273.97% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
